Cheng Du Sheng Nuo Biotec Co. Ltd. A - Asset Resilience Ratio

Latest as of September 2025: 3.51%

Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has an Asset Resilience Ratio of 3.51% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cheng Du Sheng Nuo Biotec Co. Ltd. A current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥67.00 Million
≈ $9.80 Million USD Cash + Short-term Investments

Total Assets

CN¥1.91 Billion
≈ $279.37 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2024)

This chart shows how Cheng Du Sheng Nuo Biotec Co. Ltd. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cheng Du Sheng Nuo Biotec Co. Ltd. A total assets.

Liquid Assets Composition Over Time

This chart breaks down Cheng Du Sheng Nuo Biotec Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Cheng Du Sheng Nuo Biotec Co. Ltd. A for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥67.00 Million 3.51%
Total Liquid Assets CN¥67.00 Million 3.51%

Asset Resilience Insights

  • Limited Liquidity: Cheng Du Sheng Nuo Biotec Co. Ltd. A maintains only 3.51% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Cheng Du Sheng Nuo Biotec Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Cheng Du Sheng Nuo Biotec Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Piramal Pharma Limited
NSE:PPLPHARMA
Drug Manufacturers - Specialty & Generic 0.73%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2021–2024)

The table below shows the annual Asset Resilience Ratio data for Cheng Du Sheng Nuo Biotec Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.22% CN¥20.16 Million
≈ $2.95 Million
CN¥1.65 Billion
≈ $241.14 Million
-2.58pp
2023-12-31 3.80% CN¥50.00 Million
≈ $7.32 Million
CN¥1.32 Billion
≈ $192.53 Million
-17.11pp
2021-12-31 20.91% CN¥200.00 Million
≈ $29.27 Million
CN¥956.62 Million
≈ $139.98 Million
--
pp = percentage points

About Cheng Du Sheng Nuo Biotec Co. Ltd. A

SHG:688117 China Drug Manufacturers - Specialty & Generic
Market Cap
$553.88 Million
CN¥3.79 Billion CNY
Market Cap Rank
#11823 Global
#3391 in China
Share Price
CN¥24.05
Change (1 day)
+1.35%
52-Week Range
CN¥21.44 - CN¥46.10
All Time High
CN¥48.78
About

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more